I
IBI EXPO 2023
Biological innovative drugs have become a battleground for the biopharmaceutical industry. In the 'post-pandemic era' when domestic companies continue to invest in innovative drug research and development, differentiated development, indication selection, combination therapy, external cooperation, etc., have increasingly become important ways to enhance the competitiveness of companies in new drug research and development. They are also the main path for domestic pharmaceutical companies to go global and engage in competitive globalization. In addition, a complete and mature supply chain is indispensable for industry development. How to select the most suitable raw materials, consumables, and equipment throughout the entire life cycle of new drug research and development has always been a challenge for companies. In today's world where global supply chains are still fragile,CDMOThe domestic substitution of supply chains has become a new perspective for many companies in the industry to focus on for achievement transformation.
To further promote the development of China's biopharmaceutical industry, assist startups in transforming their technological achievements, and deeply understand the global trends in the development of the biopharmaceutical industry, organized by the Shanghai Biopharmaceutical Industry Promotion Center and MedMakers MediaIBI EXPO 2023The International Bio-Innovative Drugs Industry Conference is held at7month13 - 15The day witnessed the grand opening of the Shanghai Cross-border Procurement Exhibition Center.
current sessionIBI EXPOSet proximity10,000 meters 2 Exhibition scale, concentration100+Well-known brand manufacturer in the supply chain pharmaceutical industry; by200+authorityPILed by industry leaders, passionately crafted18+The thematic forum comprehensively covers the current industry's hot topics and cutting-edge developments. A multitude of guests, including government representatives, corporate executives, renowned industry experts, and investors, gather together to participate in the industry's grand event and seek common development for the industry.
Swipe left and right to view photos of the scene
Frost & SullivanFrost & SullivanAs the strategic partner of this year's conference, Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, attended the conference, participated in the Second Rare Disease Drug Development Forum and ChinaBiotechcompanyIPO listingSpecial forum on2022 - 2023Biotechnology Market Investment and Financing Analysis' speech was delivered, followed by participation in a roundtable forum, where experts from various industries discussed the current state and development opportunities of the Hong Kong capital market with each other.
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Overall Biomedical market Investment and financing situation The number and amount of investment and financing events in China's primary market are as follows:2021year,2020Peaks are reached annually, followed by a decline.2022year,2023 H1Biopharmaceutical industry financingTop 5The amounts all exceed5Yi billion yuan, mainly for protein drugs. Looking at sub-sectors, the total financing amount for monoclonal antibody drugs closely follows that of small molecules. New therapies such as cells, genes, and nucleic acids receive high attention, with more than60pieces. Data shows that the investment and financing rounds in China's primary market are mainly concentrated inAPreviously, there was an overall trend towards earlier financing rounds. The secondary market trends in Hong Kong, Mainland China, and the US were consistent, with valuations pulling back, which also affected the financing situation in the primary market to a certain extent.
Medical device market of The total amount of investment and financing is then2020Year-over-year leap and2021Peaking at the end of the year,2023 H1Gradually slowing down. Looking at sub-sectors, robotics, surgical instruments, and artificial organs rank among the top three in terms of total investment and financing. Similar to the biopharmaceutical sector, investment and financing events in the medical device sector are also mainly concentrated inAIn the earlier stages, the proportion was on average greater than70%While the secondary market valuations in both the mainland and Hong Kong have corrected, the primary market has returned to rationality.2018till2023 H1Hong Kong stocks18AAnd the fifth set listed on the Sci-tech Innovation Board15Home medical device company, listed on the Hong Kong stock market18Aexist14Enterprises go public, Sci-tech Innovation Board No.5wrapped1Enterprises go public.
Mao Hua pointed out, Affected by macro factors such as the Fed's interest rate hikes and the fading of "epidemic-driven" effects, coupled with domestic industry factors such as severe homogenization in the biotechnology field and still weak self-sustaining capabilities, the primary and secondary investment and financing markets for biotechnology in China are in2022The callback starts at the beginning of the year.2023 H1The industry has reached a peak, with both volume and value declining severely, but it has also contributed to the rational development of the industry.
In the future, innovative biotech companies will have more diverse listing options on the secondary market (Hong Kong stock market18AThe secondary market, including the Sci-tech Innovation Board (STAR Market), Growth Enterprise Market (GEM), and Beijing Stock Exchange (BSE), places more emphasis on and anticipates a company's commercialization capabilities and self-sustaining financing. Overseas expansion capabilities and cooperation with large enterprises are considered key project strengths.
Under the chairmanship of Liu Hui, founder of Huize Finance, Mao Hua was joined by Sun Ming, Assistant Vice President of the Hong Kong Exchanges, and the Investment Banking Business Department of Lingfeng Capital LimitedCEOLi Dequan, Shenwan Hongyuan (Hong Kong) Managing Director Xie Jinghui, Ernst & Young's China Market Director Li Zhiguang, Partner Zhu Honghe of Beijing Jingtian Gongcheng Law Firm, Partner Chen Haotian of Beijing Tongshang Law Firm, Partner Huang Chengyang of Morgan Lewis Law Firm, Partner Ma Junning of Luo Xiaxin Law Firm, and guest Xia Xia from Beijing Sanliyihé Ze Biotechnology Co., Ltd. gathered together to discuss the current situation and development opportunities of biotech companies in the Hong Kong capital market.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences. Leveraging the global think tank resources of Frost & Sullivan and its cross-industry business development platform in Greater China, the Healthcare Practice has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare Has a wide range of corporate clients in China, and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
2023Frost & Sullivan's New Investment Conference
